Voyager Therapeutics’ Q4 2024 Earnings Call: Key Insights
On March 11, 2025, Voyager Therapeutics, Inc. (NASDAQ: VYGR) held its Fourth Quarter and Year-End 2024 Financial Results Conference Call. The call was led by Trista Morrison, Chief Corporate Affairs Officer and Chief of Staff to the CEO, Alfred Sandrock, President and CEO, Toby Ferguson, Chief Medical Officer, Todd Carter, Chief Scientific Officer, and Nathan Jorgensen, Chief Financial Officer. Participating analysts included Jack Allen from Robert W. Baird, Phil Nadeau from TD Cowen, Pete Stavropoulos from Cantor Fitzgerald, Lili Nsongo from Leerink Partners, Samantha Semenkow from Citi, Mehdi Goudarzi from Truist Securities, Ry Forseth from Guggenheim Securities, Jay Olson from Oppenheimer & Co., Patrick Trucchio from HC Wainwright & Co., and Yun Zhong from Wedbush Sciences, Yanan Zhu from Wells Fargo Securities, and Sumant Kulkarni from Canaccord Genuity.
Financial Highlights
During the call, Voyager Therapeutics reported a net loss of $115.1 million for the fourth quarter of 2024, compared to a net loss of $107.6 million in the same period the previous year. The company’s revenue for the quarter was $0.1 million, compared to $0.2 million in the fourth quarter of 2023. The increase in net loss was primarily due to higher research and development expenses, general and administrative expenses, and stock-based compensation expenses.
Clinical Updates
Voyager Therapeutics provided updates on its clinical programs. In Parkinson’s disease, the company reported that the first patient has been dosed in the VY-AADC01 Phase 3 trial for advanced Parkinson’s disease. Voyager also announced that it has initiated the VY-FXN01 Phase 1/2 trial for Friedreich’s Ataxia. In Huntington’s disease, the company reported that it has initiated the VY-HTT01 Phase 1/2 trial in collaboration with Roche.
Collaboration Updates
Voyager Therapeutics also announced that it has entered into a strategic collaboration with Biogen to develop and commercialize gene therapies for neurodegenerative diseases. Under the terms of the agreement, Biogen will make an upfront payment of $350 million to Voyager, and Voyager is eligible to receive up to $1.1 billion in potential milestone payments. Voyager will also be eligible to receive royalties on net sales of any products developed under the collaboration.
Impact on Individual Investors
The financial results and clinical updates reported by Voyager Therapeutics during the call may have an impact on individual investors. The company’s net loss for the quarter was higher than expected, which may cause some concern. However, the progress being made in its clinical programs and the strategic collaboration with Biogen could be seen as positive developments. It is important for investors to carefully consider their investment objectives, risk tolerance, and financial situation before making any investment decisions.
Impact on the World
The work being done by Voyager Therapeutics and other companies in the gene therapy field has the potential to make a significant impact on the world. Gene therapies have the ability to treat genetic disorders at their root cause, rather than just managing symptoms. The collaboration between Voyager and Biogen could lead to the development of new and effective treatments for neurodegenerative diseases, which affect millions of people worldwide.
Conclusion
Voyager Therapeutics’ Fourth Quarter and Year-End 2024 Financial Results Conference Call provided important updates on the company’s financial performance and clinical programs. The net loss for the quarter was higher than expected, but the progress being made in its clinical programs and the strategic collaboration with Biogen could be seen as positive developments. The potential impact of gene therapies on the treatment of genetic disorders and neurodegenerative diseases is significant, and investors and the world as a whole will be watching closely as Voyager and other companies in the field continue to make progress.
- Voyager Therapeutics reported a net loss of $115.1 million for the fourth quarter of 2024
- The company has initiated clinical trials for Parkinson’s disease, Friedreich’s Ataxia, and Huntington’s disease
- Voyager has entered into a strategic collaboration with Biogen to develop and commercialize gene therapies for neurodegenerative diseases
- The potential impact of gene therapies on the treatment of genetic disorders and neurodegenerative diseases is significant
